Free Trial

Mind Medicine (MindMed) (MNMD) Competitors

Mind Medicine (MindMed) logo
$8.44 -0.65 (-7.15%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$8.62 +0.18 (+2.07%)
As of 08/1/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MNMD vs. KYMR, CRNX, MOR, ALVO, RXRX, MIRM, CPRX, NAMS, GMTX, and RARE

Should you be buying Mind Medicine (MindMed) stock or one of its competitors? The main competitors of Mind Medicine (MindMed) include Kymera Therapeutics (KYMR), Crinetics Pharmaceuticals (CRNX), MorphoSys (MOR), Alvotech (ALVO), Recursion Pharmaceuticals (RXRX), Mirum Pharmaceuticals (MIRM), Catalyst Pharmaceuticals (CPRX), NewAmsterdam Pharma (NAMS), Gemini Therapeutics (GMTX), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "pharmaceutical products" industry.

Mind Medicine (MindMed) vs. Its Competitors

Mind Medicine (MindMed) (NASDAQ:MNMD) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

27.9% of Mind Medicine (MindMed) shares are held by institutional investors. 2.5% of Mind Medicine (MindMed) shares are held by insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Mind Medicine (MindMed) has a beta of 2.49, suggesting that its stock price is 149% more volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.18, suggesting that its stock price is 118% more volatile than the S&P 500.

Mind Medicine (MindMed) has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -409.07%. Kymera Therapeutics' return on equity of -30.11% beat Mind Medicine (MindMed)'s return on equity.

Company Net Margins Return on Equity Return on Assets
Mind Medicine (MindMed)N/A -47.29% -38.29%
Kymera Therapeutics -409.07%-30.11%-25.65%

Mind Medicine (MindMed) currently has a consensus target price of $24.00, indicating a potential upside of 184.36%. Kymera Therapeutics has a consensus target price of $59.11, indicating a potential upside of 37.60%. Given Mind Medicine (MindMed)'s stronger consensus rating and higher possible upside, equities research analysts plainly believe Mind Medicine (MindMed) is more favorable than Kymera Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mind Medicine (MindMed)
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
2 Strong Buy rating(s)
3.22
Kymera Therapeutics
0 Sell rating(s)
1 Hold rating(s)
16 Buy rating(s)
3 Strong Buy rating(s)
3.10

In the previous week, Mind Medicine (MindMed) had 2 more articles in the media than Kymera Therapeutics. MarketBeat recorded 10 mentions for Mind Medicine (MindMed) and 8 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 1.25 beat Mind Medicine (MindMed)'s score of -0.09 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mind Medicine (MindMed)
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Kymera Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Mind Medicine (MindMed) has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Mind Medicine (MindMed), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mind Medicine (MindMed)N/AN/A-$108.68M-$1.53-5.52
Kymera Therapeutics$47.07M59.43-$223.86M-$3.10-13.86

Summary

Mind Medicine (MindMed) beats Kymera Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Mind Medicine (MindMed) News Delivered to You Automatically

Sign up to receive the latest news and ratings for MNMD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MNMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MNMD vs. The Competition

MetricMind Medicine (MindMed)MED IndustryMedical SectorNASDAQ Exchange
Market Cap$686.78M$3.00B$5.48B$9.51B
Dividend YieldN/A2.43%4.73%4.09%
P/E Ratio-5.5217.6228.6723.80
Price / SalesN/A179.18373.9066.58
Price / CashN/A41.9535.4557.96
Price / Book2.638.508.275.55
Net Income-$108.68M-$55.06M$3.24B$259.03M
7 Day Performance-13.52%-3.98%-3.69%-4.59%
1 Month Performance19.21%9.59%4.33%4.46%
1 Year Performance4.07%6.72%25.95%18.03%

Mind Medicine (MindMed) Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MNMD
Mind Medicine (MindMed)
1.9119 of 5 stars
$8.44
-7.2%
$24.00
+184.4%
+0.7%$686.78MN/A-5.5240News Coverage
Earnings Report
Analyst Forecast
KYMR
Kymera Therapeutics
3.5763 of 5 stars
$45.14
-2.3%
$59.11
+31.0%
-3.4%$2.94B$47.07M-14.56170News Coverage
Positive News
Upcoming Earnings
Analyst Upgrade
Analyst Revision
CRNX
Crinetics Pharmaceuticals
3.3269 of 5 stars
$30.95
-0.5%
$69.50
+124.6%
-46.5%$2.90B$1.04M-8.10210News Coverage
Positive News
Upcoming Earnings
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730
ALVO
Alvotech
3.3884 of 5 stars
$8.64
+0.1%
$16.00
+85.2%
-24.0%$2.60B$491.98M23.351,032Positive News
RXRX
Recursion Pharmaceuticals
1.5365 of 5 stars
$6.40
+9.6%
$7.00
+9.4%
-22.6%$2.60B$58.84M-3.62400Upcoming Earnings
Gap Down
High Trading Volume
MIRM
Mirum Pharmaceuticals
3.7255 of 5 stars
$51.95
+0.0%
$65.50
+26.1%
+29.6%$2.57B$336.89M-32.27140News Coverage
Positive News
Upcoming Earnings
CPRX
Catalyst Pharmaceuticals
4.8982 of 5 stars
$21.01
-0.1%
$32.83
+56.3%
+24.7%$2.56B$491.73M13.3880Positive News
Upcoming Earnings
NAMS
NewAmsterdam Pharma
3.3287 of 5 stars
$22.56
+1.6%
$41.30
+83.1%
+23.4%$2.53B$45.56M-12.004Upcoming Earnings
GMTX
Gemini Therapeutics
N/A$57.77
0.0%
N/A+38.5%$2.50BN/A-57.7730High Trading Volume
RARE
Ultragenyx Pharmaceutical
4.474 of 5 stars
$26.39
+0.3%
$83.64
+216.9%
-35.6%$2.49B$560.23M-4.491,294Analyst Revision
High Trading Volume

Related Companies and Tools


This page (NASDAQ:MNMD) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners